Share This Page
Drugs in ATC Class D05BB
✉ Email this page to a colleague
Drugs in ATC Class: D05BB - Retinoids for treatment of psoriasis
Market Dynamics and Patent Landscape for ATC Class D05BB – Retinoids for Psoriasis Treatment
What are the key market drivers for retinoids in psoriasis management?
Retinoids within ATC class D05BB are topically or systemically used for psoriasis treatment, driven by increasing prevalence and the need for effective therapies. The global psoriasis market was valued at approximately USD 4.4 billion in 2022 and is projected to grow at a CAGR of around 9% from 2023 to 2030 [1].
Key drivers include:
- Rise in psoriasis prevalence, especially in developed regions, fueled by urbanization and environmental factors.
- Advancements in retinoid formulations improving efficacy and reducing side effects.
- High unmet medical needs for moderate to severe psoriasis cases resistant to existing treatments.
- Growth in biologics has expanded overall market size, though retinoids retain a significant share in topical therapy.
What are the main therapeutic agents within ATC D05BB?
ATC class D05BB encompasses retinoids used for psoriasis, which include:
- Tazarotene: Topical retinoid with FDA approval for psoriasis plaques.
- Acitretin: Systemic retinoid for moderate to severe cases.
- Retinoic acid (tretinoin): Topical formulation used off-label for psoriasis.
- Adapalene and others: Occasionally used off-label in psoriasis management.
Market penetration varies depending on formulation and severity of disease.
What does the patent landscape look like?
The patent landscape for retinoids in D05BB is characterized by extensive filings from major pharmaceutical companies, primarily targeting formulations, delivery systems, and combination therapies.
Patent Timeline
| Year | Key Patent Events | Focus Area |
|---|---|---|
| 2000-2010 | Original patents on tazarotene, acitretin | Compound formulations and use |
| 2010-2015 | Patent filings for novel delivery systems (e.g., nanotechnology, liposomes) | Enhanced bioavailability, reduced irritation |
| 2016-2022 | Patents on combination therapies (retinoids + corticosteroids, calcineurin inhibitors) | Synergistic effects, safety profiles |
Major Patent Holders
- Galderma: Patents on tazarotene formulations, including novel topical delivery vehicles.
- Stiefel (GSK): Patents covering adapalene for anti-psoriatic use.
- Hoffmann-La Roche: Patents on acitretin crystalline forms and delivery methods.
- Diplomat Pharma and others: Filed patents for combination topicals involving retinoids.
Patent expiration milestones
- Many original compound patents expired between 2010 and 2020.
- Secondary patents on formulations and delivery methods extending into the late 2020s.
- Pending applications focus on novel delivery systems and combination treatments.
How does competition shape market entry?
Existing patents limit early-stage entry by generic companies focusing on reformulations or delivery innovations. Off-patent compounds like tretinoin face competition from newer agents and biosimilars in systemic options.
The emergence of biosimilars and advanced delivery vehicles has increased competition, but patent protections still provide exclusivity for certain formulations until patent expiry or invalidation.
What are regulatory considerations?
FDA approvals for topical retinoids focus on safety and efficacy. Patent protections often align with regulatory data exclusivity, typically lasting 5 years post-approval.
Europe's EMA follows similar timelines, with additional data exclusivity periods potentially extending market monopoly. Recent regulatory focus emphasizes reduced side effects and targeted delivery, influencing innovation and patent filings.
Key Takeaways
- The psoriasis market for retinoids within D05BB is expanding, driven by increasing disease prevalence and formulations' improved profiles.
- Major players hold extensive patent portfolios filed from 2000 to 2015, with many patents expiring between 2010 and 2020.
- Patent strategies emphasize novel delivery methods and combinations to extend exclusivity.
- Competition from generics and biosimilars is rising, but robust patent protections for advanced formulations remain.
- Regulatory timelines influence patent expiration and market entry strategies for new retinoid products.
FAQs
1. How long do patents typically last for retinoid formulations in D05BB?
Patents generally last 20 years from filing. Original compound patents expire around 2010–2015, while formulations and delivery method patents may extend to 2025–2030.
2. Are biosimilars available for retinoid-based psoriasis treatments?
Not currently. Retinoids are small molecules, not biologics; biosimilar terminology applies to biologics. But generics of off-patent retinoids are accessible.
3. What are the common combination therapies involving retinoids?
Topical retinoids are combined with corticosteroids, vitamin D analogs, or calcineurin inhibitors to enhance efficacy and reduce side effects.
4. How does patent expiry affect market dynamics?
Patents expiring open opportunities for generics, leading to price competition and broader access. Companies extend patent life through formulation innovations.
5. What regulatory hurdles impact patenting retinoids?
Regulatory approval depends on demonstrating safety and efficacy. Data exclusivity (~5 years) complements patent rights, influencing R&D timelines and patent strategies.
References
- MarketsandMarkets. (2022). Psoriasis market by type, route of administration, and region: Global forecast to 2030.
More… ↓
